임상시험 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for Clinical Trial was estimated to be worth US$ 55175 million in 2024 and is forecast to a readjusted size of US$ 98769 million by 2031 with a CAGR of 8.8% during the forecast period 2025-2031.

Clinical trial refers to a systematic research process conducted under rigorous scientific design and ethical standards to evaluate the safety, efficacy, and clinical applicability of new drugs, medical devices, biologics, or diagnostic methods. Typically divided into four phases (I-IV), clinical trials span early-stage exploratory research, large-scale confirmatory studies, and post-marketing real-world evidence collection, playing a critical role in advancing pharmaceutical innovation, medical device development, and precision medicine adoption. With the evolution of global healthcare technologies and changing disease patterns, clinical trials are shifting from traditional centralized models to decentralized, digitalized, and patient-centric designs. Supported by global multi-center networks, advanced trial management systems, and stringent regulatory frameworks, clinical trials enable life sciences companies to accelerate product commercialization. They represent both the scientific foundation and competitive strength of the healthcare innovation ecosystem.

The clinical trial industry is fueled by increasing investment in innovative pharmaceuticals and advanced medical devices, alongside growing unmet medical needs driven by evolving disease patterns. Breakthroughs in precision medicine, immunotherapies, and cell and gene therapies are transforming trial design and execution, enabling faster drug development cycles. Favorable regulatory frameworks and growing international harmonization of standards have improved the feasibility of multi-center, global trials. The integration of AI, digital platforms, and real-world data into clinical research is driving greater efficiency, intelligence, and globalization, presenting unprecedented opportunities for investors and industry players.

Key industry challenges include rising trial costs, stringent compliance requirements, and difficulties in patient recruitment. Regulatory agencies impose strict standards for data integrity, patient safety, and ethical oversight, leading to longer timelines and increased resource commitments. Variability in policies, infrastructure, and logistics between countries adds complexity to global trial management. With heightened competition in the innovative drug sector, companies face greater pressure to optimize R&D resource allocation and trial execution efficiency. Balancing scientific rigor with accelerated timelines remains a major hurdle.

Demand for clinical trials is becoming increasingly diverse and specialized as global healthcare markets advance. Precision medicine and companion diagnostics are shifting trial focus from large-scale validation to individualized studies. CROs and research institutions are evolving into full-service providers, offering project design, patient management, and data analytics. The rise of telemedicine and digital trial platforms is broadening patient participation, improving engagement, and enhancing data quality. The industry is moving toward a more patient-centric innovation model.

The upstream segment includes investigational drugs, comparators, medical devices, diagnostic tools, and trial management systems. Leading pharmaceutical and device manufacturers are driving innovation in trial methodologies and operational efficiency through technological advancements. Adoption of electronic health records (EHRs), electronic data capture (EDC), and advanced analytics platforms has improved data traceability and standardization. Additionally, supply chain optimization and regulatory harmonization are facilitating cross-border distribution of trial drugs and equipment, reinforcing the global expansion of clinical trials.

This report aims to provide a comprehensive presentation of the global market for Clinical Trial, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Clinical Trial by region & country, by Type, and by Application.

The Clinical Trial market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Trial.

Market Segmentation

By Company

• Thermo Fisher Scientific
• Myoderm
• Bilcare
• CliniChain
• Ancillare
• MESM
• ERG Holding
• Apex Medical Research
• Parexel
• PRA Health
• LabCorp
• Marken
• AmerisourceBergen (World Courier)

Segment by Type

• Instruments (Products)
• Consumables
• Others

Segment by Application

• Procurement and Supplies
• Rentals
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Clinical Trial company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Clinical Trial in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Clinical Trial in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Clinical Trial Product Introduction
• 1.2 Global Clinical Trial Market Size Forecast (2020-2031)
• 1.3 Clinical Trial Market Trends & Drivers
  • 1.3.1 Clinical Trial Industry Trends
  • 1.3.2 Clinical Trial Market Drivers & Opportunity
  • 1.3.3 Clinical Trial Market Challenges
  • 1.3.4 Clinical Trial Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Clinical Trial Players Revenue Ranking (2024)
• 2.2 Global Clinical Trial Revenue by Company (2020-2025)
• 2.3 Key Companies Clinical Trial Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Clinical Trial Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Clinical Trial
• 2.6 Clinical Trial Market Competitive Analysis
  • 2.6.1 Clinical Trial Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Clinical Trial Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Trial as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Instruments (Products)
  • 3.1.2 Consumables
  • 3.1.3 Others
• 3.2 Global Clinical Trial Sales Value by Type
  • 3.2.1 Global Clinical Trial Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Clinical Trial Sales Value, by Type (2020-2031)
  • 3.2.3 Global Clinical Trial Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Procurement and Supplies
  • 4.1.2 Rentals
  • 4.1.3 Others
• 4.2 Global Clinical Trial Sales Value by Application
  • 4.2.1 Global Clinical Trial Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Clinical Trial Sales Value, by Application (2020-2031)
  • 4.2.3 Global Clinical Trial Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Clinical Trial Sales Value by Region
  • 5.1.1 Global Clinical Trial Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Clinical Trial Sales Value by Region (2020-2025)
  • 5.1.3 Global Clinical Trial Sales Value by Region (2026-2031)
  • 5.1.4 Global Clinical Trial Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Clinical Trial Sales Value, 2020-2031
  • 5.2.2 North America Clinical Trial Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Clinical Trial Sales Value, 2020-2031
  • 5.3.2 Europe Clinical Trial Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Clinical Trial Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Clinical Trial Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Clinical Trial Sales Value, 2020-2031
  • 5.5.2 South America Clinical Trial Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Clinical Trial Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Clinical Trial Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Clinical Trial Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Clinical Trial Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Clinical Trial Sales Value, 2020-2031
  • 6.3.2 United States Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Clinical Trial Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Clinical Trial Sales Value, 2020-2031
  • 6.4.2 Europe Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Clinical Trial Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Clinical Trial Sales Value, 2020-2031
  • 6.5.2 China Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Clinical Trial Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Clinical Trial Sales Value, 2020-2031
  • 6.6.2 Japan Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Clinical Trial Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Clinical Trial Sales Value, 2020-2031
  • 6.7.2 South Korea Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Clinical Trial Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Clinical Trial Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Clinical Trial Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Clinical Trial Sales Value, 2020-2031
  • 6.9.2 India Clinical Trial Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Clinical Trial Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Thermo Fisher Scientific
  • 7.1.1 Thermo Fisher Scientific Profile
  • 7.1.2 Thermo Fisher Scientific Main Business
  • 7.1.3 Thermo Fisher Scientific Clinical Trial Products, Services and Solutions
  • 7.1.4 Thermo Fisher Scientific Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Thermo Fisher Scientific Recent Developments
• 7.2 Myoderm
  • 7.2.1 Myoderm Profile
  • 7.2.2 Myoderm Main Business
  • 7.2.3 Myoderm Clinical Trial Products, Services and Solutions
  • 7.2.4 Myoderm Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Myoderm Recent Developments
• 7.3 Bilcare
  • 7.3.1 Bilcare Profile
  • 7.3.2 Bilcare Main Business
  • 7.3.3 Bilcare Clinical Trial Products, Services and Solutions
  • 7.3.4 Bilcare Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Bilcare Recent Developments
• 7.4 CliniChain
  • 7.4.1 CliniChain Profile
  • 7.4.2 CliniChain Main Business
  • 7.4.3 CliniChain Clinical Trial Products, Services and Solutions
  • 7.4.4 CliniChain Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.4.5 CliniChain Recent Developments
• 7.5 Ancillare
  • 7.5.1 Ancillare Profile
  • 7.5.2 Ancillare Main Business
  • 7.5.3 Ancillare Clinical Trial Products, Services and Solutions
  • 7.5.4 Ancillare Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Ancillare Recent Developments
• 7.6 MESM
  • 7.6.1 MESM Profile
  • 7.6.2 MESM Main Business
  • 7.6.3 MESM Clinical Trial Products, Services and Solutions
  • 7.6.4 MESM Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.6.5 MESM Recent Developments
• 7.7 ERG Holding
  • 7.7.1 ERG Holding Profile
  • 7.7.2 ERG Holding Main Business
  • 7.7.3 ERG Holding Clinical Trial Products, Services and Solutions
  • 7.7.4 ERG Holding Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.7.5 ERG Holding Recent Developments
• 7.8 Apex Medical Research
  • 7.8.1 Apex Medical Research Profile
  • 7.8.2 Apex Medical Research Main Business
  • 7.8.3 Apex Medical Research Clinical Trial Products, Services and Solutions
  • 7.8.4 Apex Medical Research Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Apex Medical Research Recent Developments
• 7.9 Parexel
  • 7.9.1 Parexel Profile
  • 7.9.2 Parexel Main Business
  • 7.9.3 Parexel Clinical Trial Products, Services and Solutions
  • 7.9.4 Parexel Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Parexel Recent Developments
• 7.10 PRA Health
  • 7.10.1 PRA Health Profile
  • 7.10.2 PRA Health Main Business
  • 7.10.3 PRA Health Clinical Trial Products, Services and Solutions
  • 7.10.4 PRA Health Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.10.5 PRA Health Recent Developments
• 7.11 LabCorp
  • 7.11.1 LabCorp Profile
  • 7.11.2 LabCorp Main Business
  • 7.11.3 LabCorp Clinical Trial Products, Services and Solutions
  • 7.11.4 LabCorp Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.11.5 LabCorp Recent Developments
• 7.12 Marken
  • 7.12.1 Marken Profile
  • 7.12.2 Marken Main Business
  • 7.12.3 Marken Clinical Trial Products, Services and Solutions
  • 7.12.4 Marken Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Marken Recent Developments
• 7.13 AmerisourceBergen (World Courier)
  • 7.13.1 AmerisourceBergen (World Courier) Profile
  • 7.13.2 AmerisourceBergen (World Courier) Main Business
  • 7.13.3 AmerisourceBergen (World Courier) Clinical Trial Products, Services and Solutions
  • 7.13.4 AmerisourceBergen (World Courier) Clinical Trial Revenue (US$ Million) & (2020-2025)
  • 7.13.5 AmerisourceBergen (World Courier) Recent Developments

8 Industry Chain Analysis

• 8.1 Clinical Trial Industrial Chain
• 8.2 Clinical Trial Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Clinical Trial Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Clinical Trial Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer